Sex Cord-Gonadal Stromal Tumor Market Research Report – Forecast to 2030

Sex Cord-Gonadal Stromal Tumor Market Research Report: By Type (Granulosa Cell Tumor, Sertoli Cell Tumor, Others), By Diagnosis (Microscopy, Tumor Marker, Others), By Treatment (Chemotherapy, Surgery, Others), and By End-User – Global Forecast Till 2030

ID: MRFR/MED/4456-HCR | November 2022 | Region: Global | 100 Pages         

Sex Cord Gonadal Stromal Tumor Market Speak to Analyst Request a Free Sample

Sex Cord-Gonadal Stromal Tumor Market Scenario


The sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal component of the ovary and testis. This tumor comprises granulosa, thecal cells, and fibrocytes. Sex cord-gonadal stromal tumors are mostly of seven types, namely, granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, gynandroblastoma, Sex Cord Tumor with Annular Tubules (SCTAT), and Sertoli Leydig cell tumor. In humans, this type of tumor accounts for 8% of the ovarian cancers and around 5% of testicular cancers.


It is noted that the increasing cases of ovarian and testicular cancer, technological advancements, and increasing healthcare expenditure are the key factors driving the sex cord-gonadal stromal tumor market.


Various other factors such as the growing awareness about the cord-gonadal stromal tumor, unmet medical needs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the sex cord-gonadal stromal tumor .


Despite these drivers, there are some setbacks associated with the sex cord-gonadal stromal tumor market. Strict FDA regulations, a huge capital investment with low-profit margins, and poor healthcare system in low and middle-income countries may hinder the growth of the sex cord-gonadal stromal tumor to a considerable extent.


It is estimated that the sex cord-gonadal stromal tumor market is expected to grow at a CAGR of 6.60% during the forecast period of 2020–2030.


Research Methodology


 sex cord-gonadal stromal tumor market


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience



  • Medical Device Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institutes

  • Academic Institutes and Universities


Segmentation


The global nosis, treatment, and end-user.


On the basis of tumor type, the sex cord-gonadal stromal tumor market is classified as granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, Sertoli Leydig cell tumor, gynandroblastoma, and Sex Cord Tumor with Annular Tubules (SCTAT). The granulosa cell tumor is further classified as functioning tumors and non-functioning tumors.


On the basis of diagnosis, the sex cord-gonadal stromal tumor market is classified as microscopy immunohistochemistry, tumor marker, ultrasound, Magnetic Resonance Imaging (MRI), and others. The tumor marker segment is further classified as inhibin-alpha, calretinin, Melan-A, and others.


On the basis of treatment, the sex cord-gonadal stromal tumor market is classified as chemotherapy, radiotherapy, surgery, and others. The surgery segment is further classified as salpingo-oophorectomy, abdominal hysterectomy, Retroperitoneal Lymph Node Dissection (RPLND), and radical inguinal orchiectomy. The sub-segment of salpingo-oophorectomy includes unilateral salpingo-oophorectomy and bilateral salpingo-oophorectomy.


On the basis of end-user, the sex cord-gonadal stromal tumor market is segmented into hospitals and clinics, cancer research centers, research and academic institutes, and others.


Regional Analysis


The Americas dominates the sex cord-gonadal stromal tumor market owing to the increasing prevalence of ovarian cancer in this region and high healthcare expenditure. According to the American Cancer Society, around 22,240 women are likely to be diagnosed with ovarian cancer, and 14,070 women are likely to die from ovarian cancer, in 2018.


Europe holds the second position in the sex cord-gonadal stromal tumor market. The financial support provided by the government towards R&D and technological advancements are expected to drive the European sex cord-gonadal stromal tumor market. The increasing healthcare expenditure is also boosting the European sex cord-gonadal stromal tumor market.


According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014, i.e., EUR 321 billion which is further followed by France with EUR 237 billion and United Kingdom with EUR 223 billion. In the year 2016, the R&D expenditure in the pharmaceutical industry was EUR 35000 million, suggested by the European Federation of Pharmaceutical Industries and Association.


Asia Pacific is the fastest growing sex cord-gonadal stromal tumor market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015–2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014–2015.


The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the sex cord-gonadal stromal tumor market are Abbott, Abcam plc, Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company (BD), Bio SB Inc., BioCurex, BioModa, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cell Signaling Technology, Inc., Clarient, Inc., CooperSurgical Inc., Correlogic Systems, Inc., Danaher Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Gen-Probe, Inc., Hologic, Inc., Johnson & Johnson Services, Inc., Karl Storz GmbH & Co. Kg, LiNA Medical USA, Merck Millipore, PerkinElmer, Inc., Qiagen, Radient Pharmaceuticals, Thermo Fisher Scientific Inc., Veridex LLC, and others.



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   6.60% (2020- 2030)
  Base Year   2019
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Diagnosis, Treatment, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott, Abcam plc, Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company (BD), Bio SB Inc., BioCurex, BioModa, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cell Signaling Technology, Inc., Clarient, Inc., CooperSurgical Inc., Correlogic Systems, Inc., Danaher Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Gen-Probe, Inc., Hologic, Inc., Johnson & Johnson Services, Inc., Karl Storz GmbH & Co. Kg, LiNA Medical USA, Merck Millipore, PerkinElmer, Inc., Qiagen, Radient Pharmaceuticals
  Key Market Opportunities   Growing awareness about the cord-gonadal stromal tumor, increasing government assistance, and rising funding and reimbursement
  Key Market Drivers

  • Increasing prevalence of ovarian and testicular cancer
  • Increasing healthcare expenditure


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    A sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal component of the ovary and testis. 

    The market is expected to exhibit a strong 6.5% CAGR over the forecast period from 2020 to 2030.

    The increasing prevalence of ovarian and testicular cancer is the major driver for the global market.

    Americas dominate the global sex cord-gonadal stromal tumor market.

    Leading players in the Sex Cord-Gonadal Stromal Tumor Market include Abbott, Bio-Rad Laboratories, and Karl Storz, among others.